Can You Sell a Veterinary Practice With Declining Revenue? A 2026 Owner’s Guide

Key takeaways

• Declining revenue alone does not make a practice automatically unsellable. Buyers examine why the top line changed and whether repeatable earnings remain after the owner leaves.
• Revenue, visits, profit, and normalized EBITDA are different measures. A useful sale analysis separates them before drawing a conclusion about value.
• No universal discount or recovery period applies to every practice. The cause, evidence, owner capacity, doctor coverage, and durability of any improvement change the decision.
• Add-backs need proof. A supported one-time or owner-specific expense may be adjusted, while ordinary recurring costs remain part of the practice.
• Market activity is not a promise of buyer demand. Compare qualified buyers using the same current financial and operating record.

The same scene has played out often enough that I now treat it as a composite: an owner slides a stack of monthly reports toward me over dinner and points to the falling revenue line.

The owner expects me to say the practice has become unsellable. I ask a different question: what changed underneath the top line?

Within Transitions Elite’s focus on $2M-plus U.S. companion-animal general practices, declining revenue does not automatically prevent a sale.

Buyers examine normalized EBITDA, repeatable operating profit after supported adjustments, plus visit trends, doctor coverage, and the evidence behind the decline. Profitability and transferability matter more than one revenue percentage.

Is your veterinary practice declining, or is the 2026 market softer?

Begin with both comparisons: your practice against its own history, and your practice against a clearly defined market sample.

National data shows visits and revenue can move in opposite directions, but it cannot explain your hospital without local records, a consistent accounting method, and the operating changes behind each month.

AVMA reported that client visits fell about 3% in 2025, while revenue increased about 2.5%; higher prices increasingly carried growth, and only 32% of respondents reported improved profitability.

The low point? The smallest share in several years.

Vetsource Veterinary Analytics found a similar split in its October 2025 panel.

Across 6,412 practices averaging about $2.2 million in revenue, trailing-12-month revenue, meaning the most recent 12 months, rose 2.2% while visits fell 2.9%.

Useful? Absolutely.

It is still a panel, not a forecast for your location, service mix, pricing, doctor coverage, or client base.

iVET360’s 2026 benchmark announcement reported 2.6% revenue growth, a 4.7% decline in transaction volume, and a 7.5% rise in average transaction charge; those measures belong together.

Why? Revenue growth created by higher charges is different from growth created by more client visits.

A broad decline provides context, but it does not explain weak reporting, lost doctors, falling client activity, compressed profit, or an owner who no longer has capacity to lead the practice.

What should you measure beneath declining veterinary revenue in 2026?

Measure revenue, visits, active clients, provider production, expenses, and normalized EBITDA separately. Each line answers a different question.

Then connect every material change to dated evidence, because one top-line percentage cannot stand in for the practice’s doctors, clients, expenses, owner hours, and operating story.

Revenue is the top line before expenses; as the national 2025 data illustrates, it can rise while patient volume falls and still reveal nothing by itself about profit.

Visits show clinical traffic. Active clients show how many client relationships remain current, while provider production shows who generated the work.

Profit is what remains after expenses under the accounting definition being used. Normalized EBITDA goes one step further.

Normalized EBITDA means operating profit before interest, taxes, depreciation, and amortization, adjusted for supported owner-specific and one-time items so a buyer can assess repeatable earnings under new ownership.

Measure	What it tells you	What it does not prove
Revenue	Total top-line income	Repeatable profit or buyer value
Visits	Patient traffic over time	Price quality or client retention alone
Active clients	Current client relationships under the reporting definition	That every client will return or transfer
Provider production	Which doctors generated clinical revenue	Whether the same production continues after a sale
Operating profit	Earnings under the stated accounting presentation	That every expense reflects new ownership
Normalized EBITDA	Estimated repeatable operating earnings after supported adjustments	A guaranteed price, multiple, or closing
One-time expense	A documented nonrecurring cost	An automatic add-back accepted by every buyer

Start there. I want that table filled with monthly practice data because a decline needs a diagnosis, not a slogan.

Does declining revenue automatically reduce veterinary practice value in 2026?

No fixed discount applies to every declining practice. Buyers assess the size, duration, cause, profitability effect, and transferability of the change.

A practice with softer visits and durable normalized EBITDA presents differently from one losing revenue, doctors, active clients, provider production, and operating profit at the same time.

One phrase: “declining revenue.” Several very different facts.

A practice slipping modestly after owner hours fall is not identical to one simultaneously losing doctors, clients, provider production, and operating margin.

I would not publish a formula that pretends those conditions deserve one discount. The verified valuation literature does not support one.

A multiple is the multiplier applied to EBITDA when estimating practice value. Published multiple estimates cover different samples.

QuantPillar’s Q1 2026 guide lists an 8x-14x EBITDA range for veterinary practices and calls the trend stable.

Octus described private practice acquisitions in the mid- to high single digits.

Same topic, different samples. Practice size, profitability, doctor count, growth potential, client quality, and the sale process can all change what a buyer proposes.

That wide literature is the point: do not choose a multiple first and then force declining earnings, unsupported forecasts, or optimistic adjustments to fit it later.

A veterinary trade publication states the durable principle more plainly: low-profit practices have low values. Its no-lo discussion identifies outdated pricing, high cost of goods, excessive payroll, and reduced owner availability among value problems.

A no-lo practice has no or exceptionally low value because profitability has eroded over time; one soft revenue period, by itself, does not establish that condition.

Separate the problems first. Revenue and expense structure can weaken together, or one can move while the other holds.

Only then request a current veterinary practice valuation.

Can add-backs repair declining normalized EBITDA in 2026?

An add-back is a supported adjustment for an owner-specific or one-time expense when calculating normalized EBITDA. It can clarify repeatable earnings but cannot erase an operating decline.

Ordinary payroll, inventory, occupancy, and recurring costs remain expenses after a planned sale. Removing them would only create a misleading profit figure.

No shortcut. The proposed adjustment might involve a documented event-specific cost or an owner-specific expense, but buyer acceptance depends on the evidence and deal facts.

I separate adjustments into distinct folders.

• Owner-specific items: expenses tied to the current owner’s choices rather than ordinary practice operations.
• Documented one-time items: costs caused by a specific event that is not expected to recur.
• Recurring operations: payroll, inventory, rent, software, routine repairs, and other costs needed to run the practice.

No exceptions for discomfort. The third folder does not become an add-back merely because a recurring cost hurts the answer.

The same discipline applies to owner compensation. The analysis should use a defensible market replacement cost rather than pretending the departing owner’s clinical or leadership work becomes free.

I also reject forecast add-backs. A hoped-for hire, future price increase, unfilled appointment book, or planned expense cut is not historical normalized EBITDA.

Forecasts may help a buyer understand a plan, but they should remain visibly separate from the revenue, expenses, provider production, and earnings the practice has already demonstrated.

This is where clean monthly books matter. Invoices, payroll reports, contracts, provider production, and general-ledger detail let a reviewer test each adjustment.

Proof first. If an adjustment cannot survive a basic evidence request, it should not carry the valuation story presented to qualified buyers.

Should you stabilize declining revenue before selling in 2026?

Stabilizing first may fit when the cause is controllable, the owner has capacity, and improvements can become repeatable. No fixed recovery period guarantees value.

Selling now may fit when delay adds operating, health, staffing, or owner-capacity risk; compare both paths with current evidence rather than a promised sale window or automatic value claim.

I begin with controllability.

Outdated pricing, missed charges, inventory leakage, weak reminder systems, and unclear scheduling may be addressable, while a shrinking local market or owner-capacity limit may be harder to change.

AVMA’s 2024 profitability coverage lists practice benchmarking, staffing ratios, and service mix among operating levers owners can examine.

It reported examinations and consultations at 23.5% of average practice revenue, pharmacy at 13.6%, laboratory at 12.2%, and vaccinations at 12%.

Context only. Those percentages describe an average sample; they do not tell your practice which service to grow, how clients will respond, or what next year’s revenue will be.

iVET360 published a single-practice case in which EBITDA rose 3.8 percentage points to 22.4% alongside higher revenue and average transaction charge.

That case proves an operating improvement can be measured, but it does not establish a typical recovery, a required timeline, a buyer response, or a valuation gain for your practice.

An older Veterinary Practice News no-lo article offers practical examples: missed charges and poorly controlled inventory. Its 2013 date makes it an operating illustration, not a current benchmark.

I want improvements to appear consistently in monthly records. One month is one month.

Use a simple scorecard:

Stabilization question	Evidence to review
Cause controllability	Pricing, schedule, staffing, reminder, service, and expense records
Repeatability	A pattern across current monthly closes, not one exceptional period
Profit alongside revenue	Operating profit and normalized EBITDA beside top-line growth
Team sustainability	Provider production, workload, retention, and leadership coverage
Owner capacity	A realistic clinical, management, health, and family calendar

The EBITDA benchmarks for veterinary practice sales explain why profit quality belongs beside the recovery story.

If the owner cannot sustain the work, waiting is not neutral; a forecast built on exhausted leadership, unstable staffing, or unsupported growth can make the practice harder to explain later.

Will buyers consider a veterinary practice with falling revenue in 2026?

They may, but sector activity cannot predict demand for one practice. Current earnings, scale, location, doctor coverage, transition risk, and buyer strategy still matter.

Use market data only to establish context, then let qualified written proposals show whether buyers value the specific practice, transition, evidence, and transaction terms.

Capstone Partners’ April 2026 tally showed 18 announced or completed pet-sector transactions, compared with 8 during the prior-year period.

Veterinary and health led that broad count with 9 transactions. The numbers cover a pet-sector sample, not companion-animal general-practice sales alone.

Octus’s credit analysis of veterinary operators showed uneven financial conditions among the groups it examined. I treat buyer capacity as something to verify, not assume.

Frontiers’ 2025 peer-reviewed review estimated consolidator ownership at about 75% of specialty and emergency practices and about 25% of primary-care practices.

Together, the paper said consolidator-owned practices represented roughly 50% of nationwide veterinary revenue.

A meaningful buyer segment remains for owners to evaluate alongside individual veterinarians.

Any buyer’s financing and leadership capacity still need independent testing. Familiarity does not answer affordability.

I avoid claims that buyers “always discount” a decline or “prefer” one profile. Those conclusions depend on the practice and the written process.

The useful evidence is a qualified buyer reviewing current records and submitting written terms.

How does a competitive process help a declining veterinary practice in 2026?

A private competitive process lets qualified buyers interpret the same current evidence and propose their own price, structure, conditions, and transition.

Competition does not erase the decline; it prevents one buyer’s interpretation from becoming the owner’s only direct market evidence.

I want the financial story consistent before buyers enter. Every qualified bidder should see the same revenue bridge, visit trend, provider production, adjustments, and explanation.

Fair comparison. The process also exposes where qualified buyers genuinely disagree about the practice’s risks, strengths, and transition.

One buyer may focus on doctor coverage. Another may place more weight on local density, client retention, or unused capacity.

Their written proposals reveal those differences without requiring the owner to forecast buyer preferences, invent a universal discount, or assume one inquiry represents the whole market.

With our Elite Selling System, I treat the buyer list like a velvet-rope venue: a doorman hand-selects who gets inside, and only those vetted buyers enter the private competition.

For a declining practice, the doorman matters because I would rather invite buyers capable of understanding the operating facts than circulate sensitive financial, staffing, and client records widely.

The comparison sheet should keep the columns honest:

Offer component	Question to answer
Fixed consideration	What is stated and not contingent on future performance?
Delayed or contingent value	Which conditions control payment, and who controls them?
Buyer-held amount	What release terms apply?
Transition work	What does the seller actually have to do after closing?
Closing conditions	What still must be approved, financed, verified, or delivered?

The 2026 guide to selling a veterinary practice explains the wider process. Declining revenue makes evidence discipline more important, not optional.

What should you do next with declining veterinary revenue in 2026?

Build a monthly diagnostic, document each material change, test normalized EBITDA, and obtain a current valuation. Do not choose between sell now and stabilize first from revenue alone.

Then compare owner capacity, controllability, buyer evidence, and waiting risk so the next step creates genuine options.

Start simple. Pull the available monthly closes, then put revenue, visits, active clients, provider production, payroll, cost of goods, and operating profit on one page.

Then annotate the changes. Mark a doctor departure, reduced owner hours, pricing change, unusual expense, local disruption, or service change only when records support it.

Build a second page for normalized EBITDA. List each proposed adjustment, its amount, supporting document, and reason it should not continue.

Separate page. Keep forecasts away from historical results, supported adjustments, and the normalized EBITDA presented as already demonstrated.

Now compare both paths.

• Sell now: establish current value, preserve operations, prepare the explanation, and test qualified buyer terms.
• Stabilize first: choose controllable measures, assign owners, review monthly evidence, and set a decision point rather than a promised outcome.

The timing framework in when to sell a veterinary practice can help frame owner readiness beside the financial record.

If you want the current numbers reviewed privately, request a free, confidential practice value estimate.

Bring the monthly evidence, not a polished forecast, because I want to know what changed, what remains profitable, what depends on the owner, and which options are still real.

---

Frequently asked questions

Can I sell my veterinary practice if revenue is declining in 2026?

Yes. Declining revenue does not make a veterinary practice automatically unsellable.

Buyers examine normalized EBITDA, visits, active clients, doctor coverage, owner dependence, and the evidence behind the change.

A sale remains possible, but no article can promise a buyer, price, structure, or closing.

Does declining revenue create an automatic valuation discount in 2026?

No fixed discount applies to every practice. Buyers assess the size, duration, cause, profitability effect, and transferability of the decline.

A practice with lower visits but durable normalized EBITDA presents differently from one losing revenue, doctors, clients, and profit together.

Do buyers care more about revenue or profit in 2026?

Buyers review both, but revenue alone does not show what the practice earns. Normalized EBITDA estimates repeatable operating profit after supported adjustments.

Buyers also examine visits, active clients, provider production, staffing, and owner dependence to decide whether those earnings can continue.

Can one-time expenses be added back before a 2026 veterinary practice sale?

Some supported owner-specific or nonrecurring expenses may qualify as add-backs when calculating normalized EBITDA. Ordinary recurring costs do not disappear because a sale is planned.

Document each adjustment, explain why it will not continue, and expect buyers to test it during financial review.

How long must revenue recover before I sell in 2026?

There is no universal recovery period. Buyers need enough current, consistent evidence to judge whether a change is durable, and the required evidence varies by cause and practice.

Use monthly revenue, visits, provider production, staffing, and normalized EBITDA instead of promising that a certain number of months guarantees value.

Will buyers consider a veterinary practice with falling visits in 2026?

They may. National veterinary data also shows softer visits, so a buyer should compare your practice with the market and its own history.

Sector transaction counts cannot predict demand for one practice. Current earnings, doctor coverage, location, scale, and transition risk still matter.

Should I stabilize my veterinary practice before selling in 2026?

Stabilizing first may fit when the cause is controllable, the owner has capacity, and the improvements can become repeatable. Selling now may fit when waiting adds more operational or personal risk.

Compare both paths using current evidence; neither timing choice guarantees a better outcome.

What is the first step before selling a declining veterinary practice in 2026?

Build a monthly diagnostic showing revenue, visits, active clients, provider production, staffing, expenses, and normalized EBITDA. Then document the cause of each material change and obtain a current valuation.

That work separates a top-line decline from a deeper operating problem before buyers interpret it for you.

---

Sources

Veterinary demand, client activity, and practice benchmarks

1. American Veterinary Medical Association. “Veterinarians Report Increasing Price Sensitivity, Decreasing Visits.” February 13, 2026. avma.org
2. Vetsource Veterinary Analytics. “Veterinary Industry Summary, October 12-18, 2025.” October 21, 2025. veterinaryanalytics.com
3. iVET360. “2026 Veterinary Industry Benchmark Report.” April 9, 2026. ivet360.com

Industry M&A research and valuation context

4. QuantPillar. “2025-2026 Private Market Valuation Multiples: The Definitive Cheat Sheet.” Updated Q1 2026. quantpillar.com
5. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” January 16, 2026. octus.com

Veterinary practice operations and profitability

6. Today’s Veterinary Business. “Should You Buy a No-Lo Practice?” December 1, 2019. todaysveterinarybusiness.com
7. American Veterinary Medical Association. “Increasing Practice Profitability Requires Benchmarking, Defining Core Values.” Updated May 29, 2025. avma.org
8. iVET360. “Veterinary Hospital 3.8% EBITDA Growth.” ivet360.com
9. Veterinary Practice News. “From No-Lo Vet Practice to Profits in 7 Steps.” September 23, 2013. veterinarypracticenews.com

Transaction activity and ownership context

10. Capstone Partners. “Pet Sector M&A Update.” April 10, 2026. capstonepartners.com
11. Frontiers in Veterinary Science. “Making the Case for a Resurgent U.S. Independent Veterinary Practice Segment: A SWOT Analysis.” May 13, 2025. frontiersin.org